Vitamin D and critical illness outcomes

Current Opinion in Critical Care

Volumn 22, Issue 4, 2016, Pages 332-338

  Christopher, Kenneth B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

critical care outcomes; epigenetics; Vitamin D

Indexed keywords

COLECALCIFEROL; VITAMIN D; VITAMIN;

CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG MEGADOSE; EPIGENETICS; ETHNICITY; HOSPITALIZATION; HUMAN; LENGTH OF STAY; METABOLOMICS; NONHUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSCRIPTOMICS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; DIET THERAPY; DIETARY SUPPLEMENT; HOSPITAL MORTALITY; INTENSIVE CARE UNIT; TREATMENT OUTCOME;

CRITICAL ILLNESS; DIETARY SUPPLEMENTS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; NUTRITION THERAPY; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84975106411     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000328     Document Type: Review

References (124)

1. Mullins PM, Goyal M, Pines JM. National growth in intensive care unit admissions from emergency departments in the United States from 2002 to 2009. Acad Emerg Med 2013; 20:479-486.
2. Kersten A, Milbrandt EB, Rahim MT, et al. How big is critical care in the U.S.? Crit Care Med 2003; 31:A8.
3. Herring AA, Ginde AA, Fahimi J, et al. Increasing critical care admissions from U.S. emergency departments, 2001-2009. Crit Care Med 2013; 41:1197-1204.
4. Wunsch H, Guerra C, Barnato AE, et al. Three-year outcomes for Medicare beneficiaries who survive intensive care. JAMA 2010; 303:849-856.
5. Dowdy DW, Eid MP, Sedrakyan A, et al. Quality of life in adult survivors of critical illness: a systematic review of the literature. Intensive Care Med 2005; 31:611-620.
6. Desai SV, Law TJ, Needham DM. Long-term complications of critical care. Crit Care Med 2011; 39:371-379.
7. Heyland DK, Groll D, Caeser M. Survivors of acute respiratory distress syndrome: relationship between pulmonary dysfunction and long-term health-related quality of life. Crit Care Med 2005; 33:1549-1556.
8. Schelling G, Stoll C, Vogelmeier C, et al. Pulmonary function and healthrelated quality of life in a sample of long-term survivors of the acute respiratory distress syndrome. Intensive Care Med 2000; 26:1304-1311.
9. Neff TA, Stocker R, Frey HR, et al. Long-term assessment of lung function in survivors of severe ARDS. Chest 2003; 123:845-853.
10. Orme J Jr, Romney JS, Hopkins RO, et al. Pulmonary function and healthrelated quality of life in survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2003; 167:690-694.
11. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003; 348:683-693.
12. Lee P, Eisman JA, Center JR. Vitamin D deficiency in critically ill patients. N Engl J Med 2009; 360:1912-1914.
13. Braun A, Chang D, Mahadevappa K, et al. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med 2011; 39:671-677.
14. Braun AB, Gibbons FK, Litonjua AA, et al. Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. Crit Care Med 2012; 40:63-72.
15. Braun AB, Litonjua AA, Moromizato T, et al. Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill. Crit Care Med 2012; 40:3170-3179.
16. Amrein K, Zajic P, Schnedl C, et al. Vitamin D status and its association with season, hospital and sepsis mortality in critical illness. Crit Care 2014; 18:R47.
17. Amrein K, Schnedl C, Holl A, et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA 2014; 312:1520-1530.
18. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010; 19:2739-2745.
19. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376:180-188.
20. Dickson I. New approaches to vitamin D. Nature 1987; 325:18.
21. Minghetti PP, Norman AW. 1,25(OH)2-vitamin D3 receptors: gene regulation and genetic circuitry. Faseb J 1988; 2:3043-3053.
22. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81:353-373.
23. Akeno N, Saikatsu S, Kawane T, et al. Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1alpha, 25-dihydroxyvitamin D3. Endocrinology 1997; 138:2233-2240.
24. Adorini L, Penna G, Giarratana N, et al. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid BiochemMol Biol 2004; 89-90:437-441.
25. Mahon BD, Wittke A, Weaver V, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003; 89:922-932.
26. Heine G, Anton K, Henz BM, et al. 1alpha,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. Eur J Immunol 2002; 32:3395-3404.
27. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758:1408-1425.
28. Jeng L, Yamshchikov AV, Judd SE, et al. Alterations in vitamin D status and antimicrobial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009; 7:28.
29. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15:2579-2585.
30. Gysemans CA, Cardozo AK, Callewaert H, et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005; 146:1956-1964.
31. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134:1129-1140.
32. Moro JR, Iwata M, von Andriano UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008; 8:685-698.
33. Kankova M, Luini W, Pedrazzoni M, et al. Impairment of cytokine production in mice fed a vitamin D3-deficient diet. Immunology 1991; 73:466-471.
34. Liu PT, Stenger S, Tang DH, et al. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179:2060-2063.
35. Bikle DD. Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep 2009; 7:58-63.
36. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007; 67:1999-2012.
37. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 2010; 39:365-379; Table of contents.
38. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin Dmediated human antimicrobial response. Science 2006; 311:1770-1773.
39. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
40. Bhalla AK, Amento EP, Krane SM. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol 1986; 98:311-322.
41. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004; 75:39-48.
42. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann NY Acad Sci 2014; 1319:82-95.
43. Mariathasan S, Newton K, Monack DM, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004; 430:213-218.
44. Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11:136-140.
45. Bodnar JS, Chatterjee A, Castellani LW, et al. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet 2002; 30:110-116.
46. Jeon JH, Lee KN, Hwang CY, et al. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res 2005; 65:4485-4489.
47. Han SH, Jeon JH, Ju HR, et al. VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 2003; 22:4035-4046.
48. Schutze N, Bachthaler M, Lechner A, et al. Identification by differential display PCR of the selenoprotein thioredoxin reductase as a 1 alpha,25(OH)2-vitamin D3-responsive gene in human osteoblasts-regulation by selenite. Biofactors 1998; 7:299-310.
49. Zitman-Gal T, Golan E, Green J, et al. Vitamin D receptor activation in a diabetic-like environment: potential role in the activity of the endothelial proinflammatory and thioredoxin pathways. J Steroid Biochem Mol Biol 2012; 132:1-7.
50. Nishiyama A, Matsui M, Iwata S, et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 1999; 274:21645-21650.
51. Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 2010; 285:2227-2231.
52. Sloka S, Silva C, Wang J, et al. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation 2011; 8:56.
53. Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012; 188:2127-2135.
54. Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogenassociated molecular patterns. Eur J Immunol 2006; 36:361-370.
55. Di Rosa M, Malaguarnera G, De Gregorio C, et al. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cell Immunol 2012; 280:36-43.
56. Haddad JG, Matsuoka LY, Hollis BW, et al. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest 1993; 91:2552-2555.
57. Ponchon G, Kennan AL, DeLuca HF. 'Activation' of vitamin D by the liver. J Clin Invest 1969; 48:2032-2037.
58. Bikle DD, Gee E, Halloran B, et al. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986; 63:954-959.
59. Hattori N, Oda S, Sadahiro T, et al. YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock 2009; 32:393-400.
60. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004; 29:664-673.
61. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173:2909-2912.
62. Ginde AA, Camargo CA Jr, Shapiro NI. Vitamin D insufficiency and sepsis severity in emergency department patients with suspected infection. Acad Emerg Med 2011; 18:551-554.
63. Lange N, Litonjua AA, Gibbons FK, et al. Prehospital vitamin D concentration, mortality, and bloodstream infection in a hospitalized patient population. Am J Med 2013; 126:640.e19-640.e27.
64. Moromizato T, Litonjua AA, Braun AB, et al. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill. Crit Care Med 2014; 42:97-107.
65. Matthews LR, Ahmed Y, Wilson KL, et al. Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients. Am J Surg 2012; 204:37-43.
66. de Braganca AC, Volpini RA, Canale D, et al. Vitamin D deficiency aggravates ischemic acute kidney injury in rats. Physiol Rep 2015; 3:.
67. Amrein K, Sourij H, Wagner G, et al. Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, doubleblind, placebo-controlled pilot study. Crit Care 2011; 15:R104.
68. Mata-Granados JM, Vargas-Vasserot J, Ferreiro-Vera C, et al. Evaluation of vitamin D endocrine system (VDES) status and response to treatment of patients in intensive care units (ICUs) using an on-line SPE-LC-MS/MS method. J Steroid Biochem Mol Biol 2010; 121:452-455.
69. Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009; 179:843-850.
70. Witham MD, Dove FJ, Dryburgh M, et al. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010; 53:2112-2119.
71. Mallet E, Philippe F, Castanet M, et al. Administration of a single winter oral dose of 200 000 IU of vitamin D3 in adolescents in Normandy: evaluation of the safety and vitamin D status obtained. Arch Pediatr 2010; 17:1042-1046.
72. Holst-Gemeiner D, Gemeiner M, Pilz I, et al. Plasma 25-hydroxycholecalciferol after daily vitamin D administration in comparison with massive singledose prophylaxis (author's transl). Wien Klin Wochenschr 1978; 90:509-512.
73. Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008; 87:688-691.
74. Khaw KT, Scragg R, Murphy S. Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. Am J Clin Nutr 1994; 59:1040-1044.
75. Premaor MO, Scalco R, da Silva MJ, et al. The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit. J BoneMiner Metab 2008; 26:603-608.
76. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose vitamin D3 and mental well being: randomised controlled trial. Br J Psychiatry 2011; 198:357-364.
77. Bacon CJ, Gamble GD, Horne AM, et al. High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int 2009; 20:1407-1415.
78. von Restorff C, Bischoff-Ferrari HA, Theiler R. High-dose oral vitamin D3 supplementation in rheumatology patients with severe vitamin D3 deficiency. Bone 2009; 45:747-749.
79. Coussens AK, Wilkinson RJ, Hanifa Y, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA 2012; 109:15449-15454.
80. Bergman P, Norlin AC, Hansen S, et al. Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and doubleblind intervention study. BMJ Open 2012; 2:.
81. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a doubleblind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83:754-759.
82. Salahuddin N, Ali F, Hasan Z, et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis'. BMC Infect Dis 2013; 13:22.
83. Van den Berghe G, Van Roosbroeck D, Vanhove P, et al. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 2003; 88:4623-4632.
84. Murdoch DR, Slow S, Chambers ST, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 2012; 308:1333-1339.
85. Castro M, King TS, Kunselman SJ, et al. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA 2014; 311:2083-2091.
86. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012; 156:105-114.
87. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74:1852-1859.
88. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303:1815-1822.
89. Hall LM, Kimlin MG, Aronov PA, et al. Vitamin D intake needed to maintain target serum 25-hydroxyvitamin D concentrations in participants with low sun exposure and dark skin pigmentation is substantially higher than current recommendations. J Nutr 2010; 140:542-550.
90. Jablonski NG. The evolution of human skin and skin color. Annu Rev Anthropol 2004; 33:585-623.
91. Armas LA, Dowell S, Akhter M, et al. Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB dose and skin color. J Am Acad Dermatol 2007; 57:588-593.
92. Rockell JE, Skeaff CM, Williams SM, et al. Association between quantitative measures of skin color and plasma 25-hydroxyvitamin D. Osteoporos Int 2008; 19:1639-1642.
93. Kamboh MI, Ferrell RE. Ethnic variation in vitamin D-binding protein (GC): a review of isoelectric focusing studies in human populations. Hum Genet 1986; 72:281-293.
94. Matsuoka LY, Wortsman J, Chen TC, et al. Compensation for the interracial variance in the cutaneous synthesis of vitamin D. J Lab Clin Med 1995; 126:452-457.
95. Gallagher JC, Peacock M, Yalamanchili V, et al. Effects of vitamin D supplementation in older African American women. J Clin Endocrinol Metab 2013; 98:1137-1146.
96. Gallagher JC, Jindal PS, Smith LM. Vitamin D supplementation in young White and African American women. J Bone Miner Res 2014; 29:173-181.
97. Ross AC, Taylor CL, Yaktine AL, et al. Dietary reference intakes for calcium and vitamin D. Washington, DC: Institiute of Medicine, The National Academies Press; 2011.
98. Lehtonen-Veromaa M, Mottonen T, Irjala K, et al. Vitamin D intake is low and hypovitaminosis D common in healthy 9-to 15-year-old Finnish girls. Eur J Clin Nutr 1999; 53:746-751.
99. Vieth R, Cole DE, Hawker GA, et al. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 2001; 55:1091-1097.
100. Datta S, Alfaham M, Davies DP, et al. Vitamin D deficiency in pregnant women from a non-European ethnic minority population-an interventional study. BJOG 2002; 109:905-908.
101. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135:317-322.
102. Chemical fact sheet: vitamin D3. Washington, DC: Insecticide-Rodenticide Branch, Environmental Protection Agency; 1984.
103. Amrein K, Quraishi SA, Litonjua AA, et al. Evidence for a U-shaped relationship between prehospital vitamin D status and mortality: a cohort study. J Clin Endocrinol Metab 2014; 99:1461-1469.
104. Lee P, Greenfield JR, Seibel MJ, et al. Adequacy of vitamin D replacement in severe deficiency is dependent on body mass index. Am J Med 2009; 122:1056-1060.
105. Heaney RP. Vitamin D and calcium interactions: functional outcomes. Am J Clin Nutr 2008; 88:541S-544S.
106. Lee P, Nair P, Eisman JA, et al. Vitamin D deficiency in the intensive care unit: an invisible accomplice to morbidity and mortality? Intensive Care Med 2009; 35:2028-2032.
107. Cipriani C, Romagnoli E, Pepe J, et al. Long-term bioavailability after a single oral or intramuscular administration of 600 000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. J Clin Endocrinol Metab 2013; 98:2709-2715.
108. Romagnoli E, Mascia ML, Cipriani C, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab 2008; 93:3015-3020.
109. Spriet I, Meersseman W, de Hoon J, et al. Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med 2009; 35:603-612.
110. Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010; 21:1488-1497.
111. Bertino JS Jr, Reed MD, Halpin TC Jr. Prophylaxis and treatment of childhood rickets with parenteral cholecalciferol. JPEN J Parenter Enteral Nutr 1984; 8:556-559.
112. Goff JP, Horst RL, Littledike ET. Effect of sow vitamin D status at parturition on the vitamin D status of neonatal piglets. J Nutr 1984; 114:163-169.
113. Clements MR, Fraser DR. Vitamin D supply to the rat fetus and neonate. J Clin Invest 1988; 81:1768-1773.
114. Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multitrace element products. Nutr Clin Pract 2012; 27:440-491.
115. Kiehntopf M, Nin N, Bauer M.Metabolism, metabolome, and metabolomics in intensive care: is it time to move beyond monitoring of glucose and lactate? Am J Respir Crit Care Med 2013; 187:906-907.
116. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106:2067-2072.
117. Li Z, Chan C. Integrating gene expression and metabolic profiles. J Biol Chem 2004; 279:27124-27137.
118. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 2008; 24:139-149.
119. Christopher KB. Vitamin D supplementation in the ICU patient. Curr Opin Clin Nutr Metab Care 2015; 18:187-192.
120. O'Sullivan A, Gibney MJ, Connor AO, et al. Biochemical and metabolomic phenotyping in the identification of a vitamin D responsive metabotype for markers of the metabolic syndrome. Mol Nutr Food Res 2011; 55:679-690.
121. Elnenaei MO, Chandra R, Mangion T, et al. Genomic and metabolomic patterns segregate with responses to calcium and vitamin D supplementation. Br J Nutr 2011; 105:71-79.
122. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88:582S-586S.
123. Chung LP, Waterer GW. Genetic predisposition to respiratory infection and sepsis. Crit Rev Clin Lab Sci 2011; 48:250-268.
124. Karlic H, Varga F. Impact of vitamin D metabolism on clinical epigenetics. Clin Epigenet 2011; 2:55-61.